Navigation Links
Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease
Date:1/18/2011

ANN ARBOR, Mich., Jan. 18, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will host an Alzheimer's disease-focused Investor Day on Tuesday, February 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington Court Hotel in Ann Arbor, Michigan. Headquartered in Ann Arbor, Adeona's management team welcomes shareholders, potential investors and interested parties to join them for this scientific and corporate update of the Company.

Keynote speaker, George J. Brewer, M.D., Chairman of Adeona's Scientific Advisory Board and the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan, will provide a scientific overview of the roles zinc deficiency and copper toxicity play in patients with Alzheimer's disease and mild cognitive impairment. After the scientific update, James S. Kuo, M.D., M.B.A.., Adeona's Chairman and CEO, will provide an investor update that includes the Company's near-term plans for its zinc-based therapy for Alzheimer's disease and mild cognitive impairment that is being developed as a prescription medical food. The webcast of these presentations will be accessible via the event section on the home page of Adeona's website at www.adeonapharma.com.

Adeona's management team will greet guests during a reception from 3:00-3:45 P.M., with the scientific and corporate presentations to follow. Attendance at Adeona's Investor Day is limited due to seating availability. People interested in registering to attend should contact the Company by email at investorday@adeonapharma.com or by phone at (734) 332-7800.

The Kensington Court Hotel is located near I-94 and South State Street (Exit #177) along the Briarwood Shopping Mall circle, only 2.5 miles from downtown Ann Arbor and the University of Michigan, and 25 miles from Detroit Metropolitan Airport. The hotel address is: 610 Hilton Blvd., Ann Arbor, MI. 48108.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of our clinical  trials to be completed on time or to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona to Present at OneMedForum San Francisco 2011 Conference
2. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
3. Adeona Announces Third Quarter 2010 Financial Results and Achievements
4. Adeona to Hold Annual Shareholder Meeting
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
7. Adeona Announces Second Quarter 2010 Profitability and Achievements
8. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
9. Adeona Announces HartLab Expansion Into Microbiology Testing Services
10. NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011
11. Watson to Host Investor Day on January 21 in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
Breaking Medicine News(10 mins):